Planned maintenance may cause outages to the Department of Health and Aged Care’s network from 5:15 pm AEDT on 30 November to 10:00 pm AEDT on 1 December 2024. Access to TGA databases such as TBS Portal, ARTG and DAEN may be affected. We apologise for any inconvenience.
Results for
"[search-keyword]"
Sponsor content
25 result(s) found, displaying 1 to 10
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
Australian Public Assessment Report (AusPAR)Australian Public Assessment Report for Decitabine and cedazuridine
-
Prescription medicine decision summaryTGA decision: Inqovi 35/100 (decitabine and cedazuridine) is approved to treat adult patients with myelodysplastic syndromes and CMML.
-
Prescription medicine registrationActive ingredients: cedazuridine; decitabine.
-
Cancellation by sponsorRequested by Otsuka Australia Pharmaceutical Pty Ltd
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg tablet blister pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 15 mg + 45 mg tablet blister composite pack.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for JINARC tolvaptan 30 mg + 60 mg tablet blister composite pack.